(no title)
maest | 4 days ago
Also, even in the absence of the "indebtedness" conclusion, the subsidy argument assumes that pharma companies would reduce their R&D spend, instead of just accepting lower margins if the US could more aggressively negotiate drug prices.
No comments yet.